ABSTRACT BACKGROUND Biomarkers to predict recurrent stroke and targets of therapy to prevent stroke are lacking.
C erebrovascular disease is a major contributor to morbidity and mortality across the globe (1, 2) . In the United States, although the relative risk of dying from stroke is declining, approximately 800,000 people continue to experience new or recurrent strokes every year.
As the population ages, cerebrovascular events have the potential to reach a higher incidence than myocardial infarction (MI).
In fact, stroke burden is disproportionately higher in China, Africa, and South America compared with ischemic heart disease and with stroke rates in other counties (2) .
Although ischemic heart disease and ischemic stroke have commonalities in risk factors and underlying disease mechanisms, the strength of the association varies according to individual risk factors. Novel biomarkers and therapeutic targets would be useful to predict new or recurrent stroke and identify high-risk individuals for preventive measures.
Oxidation-specific epitopes (OSE) are a major class of atherosclerosis-relevant antigens that define oxidative modifications on lipoproteins, apoptotic cells, and proteins (3) . Present on apolipoproteins in the lipid phase as well as oxidized lipids covalently bound to amino acids on the protein moiety, OSEs share molecular identity with danger-associated molecular patterns on apoptotic cells as well as with pathogen-associated molecular patterns on microbial pathogens. OSEs are recognized by a common set of innate pattern recognition receptors, which have been evolutionarily selected to protect against the proinflammatory properties of OSEs (4, 5) . When OSEs activate arcs of immunity, the general response is to generate inflammation, which in turn mediates proatherogenic potential.
Phosphocholine-containing oxidized phospholipids (OxPLs) are well-studied OSEs that are highly immunogenic, proinflammatory, and present in atherosclerotic lesions of animals and humans, particularly in pathologically defined vulnerable and disrupted plaques (6, 7) . OxPLs are important contributors to early and late events in atherogenesis by activating proinflammatory genes in endothelial cells and macrophages (8) , leading to inflammatory cascades in the vessel wall (9) . Additionally, OxPLs on oxidized low-density lipoprotein cholesterol (LDL-C) lead to uptake of this even more damaging form of LDL-C by macrophages, promoting foam cell formation (10) . OxPL can be measured on apolipoprotein B-100 (apoB) lipoproteins (OxPL-apoB) in plasma using the E06 natural antibody that recognizes the phosphocholine head group of OxPL. Elevated OxPLapoB levels correlate with the presence of anatomical cardiovascular disease (CVD), and predict new CVD events in community-based settings in people with and without prior CVD (11) (12) (13) (14) (15) (16) . (17) . The aim of this current study was to assess the predictive value of OxPL-apoB levels, the effect of atorvastatin therapy, and their relationship to recurrent stroke or first major coronary event.
METHODS
OxPL-apoB levels were obtained from patients enrolled in SPARCL (17), a randomized trial comparing placebo versus 80 mg atorvastatin for secondary prevention of recurrent cerebrovascular events.
Participants had experienced a stroke or TIA 1 to 6 months before study entry, had LDL-C levels of 100 to 190 mg/dl (2.6 to 4.9 mmol/l), and had no known coronary heart disease, and they were randomized to double-blind treatment with 80 mg of atorvastatin/ day or placebo. The SPARCL trial's primary outcome was time from randomization to a first nonfatal or fatal stroke, the same endpoint that was used in the current substudy. Secondary endpoints were major coronary events (death from cardiac causes, nonfatal MI, or resuscitation after cardiac arrest) and any cardiovascular event. The latter covered the major coronary events plus stroke or TIA, unstable angina, any coronary event (acute coronary event plus a coronary MEASUREMENT OF OxPL-apoB LEVELS. A chemiluminescent immunoassay was used to measure OxPLapoB levels. The assay used the murine monoclonal antibody E06 that recognizes the phosphocholine group on oxidized but not native phospholipids (details in Byun et al. [16] and references therein) and results reported in nanomoles (nmol/l). The OxPLapoB measure reflects OxPL on all apoB-100-containing lipoproteins, but we have shown previously that it primarily reflects the biological activity and clinical risk of lipoprotein(a) (Lp[a] ), the major lipoprotein carrier of OxPL in plasma, by virtue of carrying w85% of OxPL on apoB-100-containing lipoproteins (3, 16, (18) (19) (20) . OxPL-apoB levels were measured in 2 batches, and a set of high and low standards were included on each plate to ensure uniformity of individual plates and to minimize batch-to-batch and plate-to-plate variability. Data from all of the standard curves from all plates were averaged and used to derive nmol/l units across all samples. Lp(a) levels were not measured in these subjects. Byun et al. of OxPL-apoB were also calculated.
RESULTS
Baseline characteristics from the main SPARCL study (n ¼ 4,731) and the OxPL-apoB biomarker substudy (n ¼ 4,385) at the time of randomization are shown in Table 1 ; in the biomarker substudy, 2,191 patients were treated with 80 mg atorvastatin and 2,194 with placebo. Of the substudy subjects, 544 had recurrent stroke and 182 had a major coronary event during the study. In the main study, the event rate for the pri- OxPL-apoB levels. The association of OxPL-apoB with events was evaluated in 4 models: The analysis of association between oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) and (A) recurrent stroke, (B) first major coronary event, and (C) any cardiovascular (CV) events was adjusted for age, sex, type of qualifying event (stroke or transient ischemic attack), investigator region, time since the qualifying event,
and difference between treatment groups.
Oxidized Phospholipids Predict Recurrent Stroke baseline OxPL-apoB and recurrent stroke ( Figure 1A) , first major coronary event ( Figure 1B) , and any cardiovascular event ( Figure 1C ).
CHANGES ACCORDING TO EVENTS AND TREATMENT
ASSIGNMENT. The median percent change in OxPLapoB levels from baseline to year 5 was À17.2% the difference between these patient groups was not statistically significant (p ¼ 0.7449) (Figure 2A ).
Similar findings were observed for median absolute change in levels of OxPL-apoB (p ¼ 0.3489).
Additionally, similar data were present for percent change in OxPL-apoB and first major coronary event and any cardiovascular event (data not shown).
In the overall cohort, the median percent change in OxPL-apoB levels from baseline to year 5 was À15.5%
(IQR: À50.4% to 48.7%) ( Figure 2B ). Receiver-operating characteristic curves for recurrent stroke were generated with 2 models for each Table 4 , adding OxPL-apoB significantly increased the AUC for prediction of recurrent stroke, major coronary events, and any cardiovascular events. Similar findings were present in the placebo and atorvastatin groups ( Table 4) .
NRI and IDI were determined for recurrent stroke, first major coronary event, and any cardiovascular event. In the total population and the atorvastatin and placebo groups, adding OxPL-apoB significantly changed both improvement indexes (Table 5) .
BASELINE LDL-C AND PRESENCE OF DIABETES
MELLITUS. We further analyzed the data by median baseline LDL-C (#132 or >132 mg/dl) and median *Analysis model also adjusted treatment effect when both treatment groups are included. LDL-C levels were matched. †Model 1 included age, sex, hypertension, DM, and HDL-C. ‡Model 2 added OxPL-apoB to model 1.
AUC ¼ area under receiver-operating characteristic curve; other abbreviations as in Table 1 . In the 15-year, prospective Bruneck study evaluating first-time events in the general community, OxPL-apoB was associated with time to first stroke, with an HR of 3.6 comparing third versus first tertile levels (14) . That study was different yet complimentary to SPARCL in that Bruneck enrolled communitybased subjects who were at much lower risk, whereas SPARCL involved much higher-risk patients who already had an event. Irrespective of these differences, the studies are pathophysiologically consistent, showing that OxPL-apoB can predict both first and recurrent cerebrovascular events. Furthermore, although this study was not designed as an outcomes study, elevated OxPL-apoB predicted first coronary events, which had a lower frequency than recurrent stroke. These data were consistent with prior observations on the association of OxPL-apoB with CAD events (11, (13) (14) (15) (16) .
The baseline and changes in AUC, as well as the IDI and NRI, were consistent with prior OxPL-apoB and Lp(a) data from subjects in the general community from the Bruneck study with prospective 15-year follow-up: baseline AUC was 0.664 using Framingham variables, which increased to 0.705 by adding OxPL-apoB (DAUC 0.041) (14) . Similarly, in a separate analysis of the Bruneck study, the AUC for Lp(a) using Values are %.
Abbreviations as in Table 1 . In SPARCL, the changes in OxPL-apoB from baseline to 5 years declined similarly in both the atorvastatin and placebo arms. Unfortunately, a sample in between these times was not available to assess whether there was a rise and fall in OxPL-apoB. One explanation for this is that the decline in OxPL-apoB levels in both groups may reflect the fact that OxPL-apoB is an acute-phase reactant that has been shown to rise substantially post-acute coronary syndrome and remain elevated for 4 to 7 months afterward (7, (36) (37) (38) (39) .
Although this has not been shown previously for stroke or TIA, the fact that OxPL-apoB levels declined in the placebo group was consistent with a prolonged acutephase response, as these patients were recruited within 1 to 6 months of the index event. A significant decline (À3.9%) in OxPL-apoB was also noted in the 
PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE:
Patients with ischemic stroke face elevated risks of recurrent cerebral or de novo coronary events despite high-intensity statin therapy, and elevated blood levels of OxPL-apoB are predictive of these events. Oxidized Phospholipids Predict Recurrent Stroke
